[Long term continuous combination of cisplatin and 5 fluorouracil in advanced breast neoplasms. A retrospective study of 77 patients].
Seventy-seven pre-treated patients with advanced breast cancer were administered a combination chemotherapy with cisplatin 50 mg/sqm d1, 5-fluorouracil 300 mg/sqm/d protracted continuous infusion d1-d28, allopurinol 600 mg/d po d1-d28, q29d. Overall response rate was 26%, median survival time 46 weeks, survival rate 43.3% at 1 year, 20.2% at 2 years, 10.6% at 3 years. Response rate was rather high in CNS and meningeal involvement (6/10).
Spaeth
D
D
Département d'oncologie médicale, Centre Alexis-Vautrin, Vandoeuvre-lès-Nancy, France.
Conroy
T
T
Krakowski
I
I
Geoffrois
L
L
Luporsi
E
E
Rios
M
M
Weber
B
B
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D002945:Cisplatin; D005472:Fluorouracil
Association cisplatine et 5-fluorouracile continu à long terme dans les cancers du sein avancés. Etude rétrospective de 77 patientes.